Vir Biotechnology, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $9.15
- 52-Week Range
- $5.45 – $14.38
- Market Cap
- $1.65B
- P/E (TTM)
- —
- EPS (TTM)
- -1.18
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.68
- PEG Ratio
- —
- Return on Equity
- -21.84%
- Return on Assets
- -12.47%
- Gross Margin
- -36.67%
- Operating Margin
- -70.21%
- Profit Margin
- -61.03%
- Current Ratio
- 6.30
- Debt/Equity
- 0.10
- Total Debt
- $90.78M
- Free Cash Flow
- $-81.92M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.20B
Market Snapshot
About
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing immunological treatments for infectious diseases. The company uses antibody platform technologies to develop therapies for diseases including hepatitis B, influenza, HIV, and COVID-19. Vir leverages deep insights into viral immunology to create potentially transformative treatments.